{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:53:59Z","timestamp":1790636039092,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.vaccine.2015.03.036","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T09:25:10Z","timestamp":1428571510000},"page":"2347-2353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials"],"prefix":"10.1016","volume":"33","author":[{"given":"Xia","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"DeRosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Keefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2015.03.036_bib0215","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol Rev"},{"issue":"12","key":"10.1016\/j.vaccine.2015.03.036_bib0220","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1128\/JVI.00183-14","article-title":"Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes","volume":"88","author":"Mann","year":"2014","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.03.036_bib0225","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.exppara.2013.09.007","article-title":"Screening of novel malaria DNA vaccine candidates using full-length cDNA library","volume":"135","author":"Shibui","year":"2013","journal-title":"Exp Parasitol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.036_bib0230","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/hum.2012.141","article-title":"Innovative DNA vaccine to break immune tolerance against tumor self-antigen","volume":"24","author":"Kang","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.vaccine.2015.03.036_bib0235","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/infdis\/jir545","article-title":"Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic","volume":"204","author":"Ahmad","year":"2011","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.03.036_bib0240","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.4049\/jimmunol.1101421","article-title":"HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable","volume":"187","author":"De Rosa","year":"2011","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.03.036_bib0245","doi-asserted-by":"crossref","first-page":"e21225","DOI":"10.1371\/journal.pone.0021225","article-title":"A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)","volume":"6","author":"Churchyard","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2015.03.036_bib0250","doi-asserted-by":"crossref","first-page":"e29231","DOI":"10.1371\/journal.pone.0029231","article-title":"Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and\/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults","volume":"7","author":"Kalams","year":"2012","journal-title":"PLoS ONE"},{"issue":"50","key":"10.1016\/j.vaccine.2015.03.036_bib0255","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1016\/j.vaccine.2009.09.060","article-title":"A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a phase I clinical trial in HIV-uninfected adults","volume":"27","author":"Jin","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.03.036_bib0260","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"Kalams","year":"2013","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2015.03.036_bib0265","doi-asserted-by":"crossref","first-page":"e24517","DOI":"10.1371\/journal.pone.0024517","article-title":"Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial","volume":"6","author":"Koblin","year":"2011","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2015.03.036_bib0270","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/infdis\/jir615","article-title":"Timing of plasmid cytokine (IL-2\/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects","volume":"204","author":"Baden","year":"2011","journal-title":"J Infect Dis"},{"issue":"1-2","key":"10.1016\/j.vaccine.2015.03.036_bib0275","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2007.02.003","article-title":"Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials","volume":"322","author":"Bull","year":"2007","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2015.03.036_bib0280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination","volume":"323","author":"Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0285","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"issue":"47\u201348","key":"10.1016\/j.vaccine.2015.03.036_bib0290","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1016\/j.vaccine.2006.06.009","article-title":"Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation","volume":"24","author":"Li","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/QAI.0b013e3180377b5b","article-title":"Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay","volume":"45","author":"Dubey","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.vaccine.2015.03.036_bib0300","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2006.07.050","article-title":"Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers","volume":"25","author":"Goepfert","year":"2007","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2015.03.036_bib0305","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.vaccine.2015.03.036_bib0310","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"Li","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00031305.1997.10473577","article-title":"Multiple tests with discrete distributions","volume":"51","author":"Westfall","year":"1997","journal-title":"Am Stat"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2015.03.036_bib0320","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jim.2006.07.015","article-title":"Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials","volume":"315","author":"Moodie","year":"2006","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0325","first-page":"119","article-title":"Approximate is better than exact for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0330","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/315229","article-title":"Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env\/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of \u03b2-chemokines","volume":"181","author":"Boyer","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0335","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0264-410X(00)00302-9","article-title":"Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of hepatitis B virus DNA vaccine","volume":"19","author":"Roy","year":"2001","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2015.03.036_bib0340","doi-asserted-by":"crossref","first-page":"10817","DOI":"10.1073\/pnas.181123498","article-title":"Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine","volume":"98","author":"Wang","year":"2001","journal-title":"PNAS"},{"issue":"155","key":"10.1016\/j.vaccine.2015.03.036_bib0345","doi-asserted-by":"crossref","first-page":"155ra138","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci Transl Med"},{"issue":"June (26)","key":"10.1016\/j.vaccine.2015.03.036_bib0350","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1016\/j.vaccine.2006.04.016","article-title":"Hepatitis A\/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors","volume":"24","author":"Van der Wielen","year":"2006","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2015.03.036_bib0355","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/ijo.2011.208","article-title":"Obesity is associated with impaired immune response to influenza vaccination in humans","volume":"36","author":"Sheridan","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0360","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.vaccine.2013.01.032","article-title":"Leptin-based adjuvants: an innovative approach to improve vaccine response","volume":"31","author":"White","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0365","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.nutres.2011.04.002","article-title":"Obestity with a body mass index under 30 does not significantly impair the immune response in young adults","volume":"31","author":"Han","year":"2011","journal-title":"Nutr Res"},{"issue":"3","key":"10.1016\/j.vaccine.2015.03.036_bib0370","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/156652321403140819122538","article-title":"Improving DNA vaccine performance through vector design","volume":"14","author":"Williams","year":"2014","journal-title":"Curr Gene Ther"},{"issue":"November","key":"10.1016\/j.vaccine.2015.03.036_bib0375","first-page":"354","article-title":"Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants","volume":"4","author":"Flingai","year":"2013","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.vaccine.2015.03.036_bib0380","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1128\/JVI.78.14.7490-7497.2004","article-title":"Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys","volume":"78","author":"Letvin","year":"2004","journal-title":"J Virol"},{"issue":"14","key":"10.1016\/j.vaccine.2015.03.036_bib0385","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1128\/JVI.79.14.8828-8834.2005","article-title":"A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates","volume":"79","author":"Barouch","year":"2005","journal-title":"J Virol"},{"issue":"26","key":"10.1016\/j.vaccine.2015.03.036_bib0390","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1016\/j.vaccine.2006.11.070","article-title":"Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques","volume":"25","author":"Chong","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2015.03.036_bib0395","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.psyneuen.2008.05.002","article-title":"Higher body mass index (BMI) is associated with reduced glucocorticoid inhibition of inflammatory cytokine production following acute psychosocial stress in men","volume":"33","author":"Wirtz","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0400","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/ATVBAHA.111.230979","article-title":"CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis","volume":"31","author":"Poitou","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0405","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000209979","article-title":"Obesity, inflammation, and macrophages","volume":"63","author":"Subramanian","year":"2009","journal-title":"Nestle Nutr Workshop Ser Pediatr Progr"},{"issue":"11","key":"10.1016\/j.vaccine.2015.03.036_bib0410","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/ijo.2013.16","article-title":"Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection","volume":"37","author":"O'Shea","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0415","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"203","author":"Goepfert","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.036_bib0420","doi-asserted-by":"crossref","first-page":"e9015","DOI":"10.1371\/journal.pone.0009015","article-title":"Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses","volume":"5","author":"Koup","year":"2010","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T08:47:06Z","timestamp":1717836426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15003357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":42,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0264410X15003357"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.036","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}